| abstract |
A sulfamide compound that responds to formula (1): wherein R1 is phenyl unsubstituted or substituted with one, two, three, four or five of any of the following: halogen, CF3, OCF3, SCF3, NO2, CN, C1-6 alkyl, C1-6 alkoxy, NR5R6, CONR7R8, S-C1-6 alkyl, CO2 (C1-6 alkyl), (C1-6 alkyl) -CO2- (C1-6 alkyl); R2 is hydrogen, halogen, CF3, CN or C1-4 alkyl; R3, R4, R7 and R8 are independently hydrogen, C1-6 alkyl, or benzyl; R5, R6 and R9 are independently hydrogen or C1-6 alkyl; X is O, S or CH2; n is 1; or one of its pharmaceutically acceptable salts. A pharmaceutical composition comprising a compound of the formula (1) and a pharmaceutically acceptable carrier or excipient. Use of a compound of the formula (1) to prepare a pharmaceutical composition to treat diseases associated with the balance of urotensin II by antagonizing the urotesin-II receptor, by administering it to a patient in need of said compound. A process for obtaining a compound of formula (1) or a pharmaceutically acceptable salt thereof comprising the hydrogenation of a compound and formula (2) wherein R9 and n are as described in claim 1, or a group convertible thereto, to give a compound of the formula (3), which is reacted with a compound of the formula: R1-SO2Cl, wherein R1 is as described in claim 1, or a convertible group in the same, and when desired or necessary, conversion of R1 and / or R9. |